Clee Medical Secures Seed Funding, Advancing Real-Time Brain Surgery Imaging
February 28, 2026, 10:30 am
Location: Germany, North Rhine-Westphalia, Bonn
Employees: 51-200
Founded date: 2005
Clee Medical secured seed funding for its Neuro Access platform. This Swiss spin-off aims to revolutionize brain surgery. The platform provides real-time, ultra-high-resolution imaging during procedures. It combines optical coherence tomography (OCT) with advanced navigation. This prevents surgical complications due to brain shift. It ensures safer, more precise minimally invasive neurosurgery. The funding accelerates clinical validation and regulatory approval. This marks a significant step for advanced neurotechnology. It promises better patient outcomes.
Brain surgery is complex. Surgeons require extreme precision. Current methods often rely on pre-operative scans. These images become less accurate. The brain shifts during an operation. This creates a critical challenge. Intraoperative visibility remains limited. Navigating delicate neural structures proves difficult. The dynamic surgical environment demands better tools. Patient safety hangs in the balance. This introduces significant risk.
Clee Medical addresses this void. Its Neuro Access platform offers a vital solution. It delivers real-time, ultra-high-resolution imaging. This happens directly inside the brain during surgery. The system integrates optical coherence tomography. OCT technology provides microscopic detail. It combines this with advanced navigation. Surgeons gain a live view. They see anatomy and critical structures with clarity. Blood vessels become visible before contact. This minimizes accidental damage risk. It supports safer, minimally invasive procedures. The platform uses a slender probe. It is no wider than existing instruments. It fits existing surgical workflows seamlessly. No new techniques or specialized equipment are needed. Neuro Access boosts confidence. It enhances precision in high-risk procedures. It improves surgical outcomes for patients.
The company recently closed its seed financing round. This marks a significant milestone. High-Tech Gründerfonds led the investment. Zürcher Kantonalbank participated. Kickfund, FONGIT, and Venture Kick also contributed. Existing investor Wyss Center Geneva continued its backing. This strong European syndicate validates Clee Medical's vision. It signals confidence in its innovative neurotechnology. The funding round propels the company forward. It accelerates its mission.
This capital injection fuels crucial next steps. It supports continued platform development. Clee Medical will expand its clinical programs. A first study with human patients is planned. This moves the technology from research to validation. Regulatory approvals are also a priority. The company aims for early clinical adoption. This funding bridges the gap. It connects scientific discovery with real-world impact. Neuro Access moves closer to operating rooms worldwide. Its market entry accelerates.
Clee Medical originated from Wyss Geneva. It spun out in December 2024. Wyss Geneva, a non-profit neuro venture builder, provided foundational research. It fosters innovation in neurological treatments. Clee Medical was founded in 2024. It is based in Geneva, Switzerland. The company earned recognition swiftly. It was named one of the Top 100 Swiss Startups in 2025. This rapid acclaim highlights its potential. Its long-term vision is clear. It seeks to empower neurosurgeons. They will operate with enhanced real-time insight. This improves safety and efficiency. Patient outcomes for complex brain procedures will rise significantly. The platform aims for wide application. Functional neurosurgery and neuro-oncology are key target areas. This broad applicability underlines its impact on medicine.
The Clee Medical team brings deep expertise. Co-founder and CEO Matt Lapinski leads the company. He possesses over a decade of experience. His background includes building and scaling Class III medical device startups. Co-founder and CTO Abed Hammoud is another key figure. He contributed to market-leading neurosurgical systems. These include Medtronic’s StealthStation. Renishaw’s NeuroMate robotic system also benefited from his input. This leadership team combines entrepreneurial drive with technical prowess. Their collective experience solidifies the company's foundation. Principal Engineer Gary Evans and Optical Systems Engineer Jules Scholler complement their skills. This diverse talent drives innovation.
This seed round signifies more than capital. It marks a pivotal shift in neurosurgical paradigms. Real-time intraoperative imaging is the future. It addresses a critical unmet need. Minimally invasive procedures benefit immensely. Surgeons gain unparalleled visibility. This reduces surgical risks dramatically. It expands treatment possibilities for various conditions. Clee Medical positions itself at the forefront of this revolution. Its innovative technology promises revolutionary changes for medical practice. Patients undergoing intricate brain procedures stand to gain considerably. The advance contributes to a new era in neurotechnology. It sets a new standard for precision medicine across the globe.
Brain surgery is complex. Surgeons require extreme precision. Current methods often rely on pre-operative scans. These images become less accurate. The brain shifts during an operation. This creates a critical challenge. Intraoperative visibility remains limited. Navigating delicate neural structures proves difficult. The dynamic surgical environment demands better tools. Patient safety hangs in the balance. This introduces significant risk.
Clee Medical addresses this void. Its Neuro Access platform offers a vital solution. It delivers real-time, ultra-high-resolution imaging. This happens directly inside the brain during surgery. The system integrates optical coherence tomography. OCT technology provides microscopic detail. It combines this with advanced navigation. Surgeons gain a live view. They see anatomy and critical structures with clarity. Blood vessels become visible before contact. This minimizes accidental damage risk. It supports safer, minimally invasive procedures. The platform uses a slender probe. It is no wider than existing instruments. It fits existing surgical workflows seamlessly. No new techniques or specialized equipment are needed. Neuro Access boosts confidence. It enhances precision in high-risk procedures. It improves surgical outcomes for patients.
The company recently closed its seed financing round. This marks a significant milestone. High-Tech Gründerfonds led the investment. Zürcher Kantonalbank participated. Kickfund, FONGIT, and Venture Kick also contributed. Existing investor Wyss Center Geneva continued its backing. This strong European syndicate validates Clee Medical's vision. It signals confidence in its innovative neurotechnology. The funding round propels the company forward. It accelerates its mission.
This capital injection fuels crucial next steps. It supports continued platform development. Clee Medical will expand its clinical programs. A first study with human patients is planned. This moves the technology from research to validation. Regulatory approvals are also a priority. The company aims for early clinical adoption. This funding bridges the gap. It connects scientific discovery with real-world impact. Neuro Access moves closer to operating rooms worldwide. Its market entry accelerates.
Clee Medical originated from Wyss Geneva. It spun out in December 2024. Wyss Geneva, a non-profit neuro venture builder, provided foundational research. It fosters innovation in neurological treatments. Clee Medical was founded in 2024. It is based in Geneva, Switzerland. The company earned recognition swiftly. It was named one of the Top 100 Swiss Startups in 2025. This rapid acclaim highlights its potential. Its long-term vision is clear. It seeks to empower neurosurgeons. They will operate with enhanced real-time insight. This improves safety and efficiency. Patient outcomes for complex brain procedures will rise significantly. The platform aims for wide application. Functional neurosurgery and neuro-oncology are key target areas. This broad applicability underlines its impact on medicine.
The Clee Medical team brings deep expertise. Co-founder and CEO Matt Lapinski leads the company. He possesses over a decade of experience. His background includes building and scaling Class III medical device startups. Co-founder and CTO Abed Hammoud is another key figure. He contributed to market-leading neurosurgical systems. These include Medtronic’s StealthStation. Renishaw’s NeuroMate robotic system also benefited from his input. This leadership team combines entrepreneurial drive with technical prowess. Their collective experience solidifies the company's foundation. Principal Engineer Gary Evans and Optical Systems Engineer Jules Scholler complement their skills. This diverse talent drives innovation.
This seed round signifies more than capital. It marks a pivotal shift in neurosurgical paradigms. Real-time intraoperative imaging is the future. It addresses a critical unmet need. Minimally invasive procedures benefit immensely. Surgeons gain unparalleled visibility. This reduces surgical risks dramatically. It expands treatment possibilities for various conditions. Clee Medical positions itself at the forefront of this revolution. Its innovative technology promises revolutionary changes for medical practice. Patients undergoing intricate brain procedures stand to gain considerably. The advance contributes to a new era in neurotechnology. It sets a new standard for precision medicine across the globe.